Japanese Pharmaceutical Market Conference (JPM)

Venue: BSG House

Location: London, United Kingdom

Event Date/Time: Feb 26, 2009 End Date/Time: Feb 26, 2009
Registration Date: Feb 25, 2009
Early Registration Date: Feb 20, 2009
Report as Spam


After the United States, the Japanese have the largest share of the $600bn global pharmaceutical market. Worth $58.5bn in 2007, IMS Health forecasts this to increase to $79bn within five years and nearly double to $105bn by 2023.

Due to its commercial size, Japan is the one major market that all pharmaceutical companies are keen to increase their share in. Furthermore, because of its prosperity and rapidly aging population, incidences of Western, 'lifestyle' diseases are also increasing, resulting in growth for areas including obesity, metabolic diseases, cancers, central nervous system diseases, type II diabetes and cardiovascular disease.

Historically, the Japanese pharmaceutical market has been one of the less-penetrable for foreign companies. It is also characterised by slower growth rates than the rest of the world, fewer opportunities for generic alternatives and aggressive government price cutting every two years. Japanese firms also have to deal with rising technology costs and $70bn worth of annual global pharmaceutical sales are due to go off-patent by 2009.

However, recent mergers involving Japanese firms have provided U.S. and European biotechs enhanced opportunities to partner with Japanese pharmas looking to fill pipelines and compete globally. As the foreign businesses acquired by Japanese pharma companies do not answer all the needs or fulfill all the possibilities, there is every reason to expect more deals. Additionally, Japanese biomedical biotechnology- worth $80bn- has exploded since 2002 and the generics market is nudging $5bn.

Visiongain’s inaugural conference on the Japanese pharmaceutical market is a unique event in today’s business environment. Attended by leading figures and key stakeholders, this senior networking event will provide you with the concentrated market intelligence you need; empowering your expansion East.

By attending the conference you will understand:
• The state of the JPM and strategic developments including drivers, opportunities, restraints and threats
• How to engage with and foster business opportunities with Japanese companies, whether in the UK, Europe or Japan
• Pharmaceutical products being developed by Japanese companies for ‘lifestyle’ diseases
• How to overcome legal, regulatory, intellectual property and pricing and reimbursement issues when entering the Japanese market
• Exciting developments in Japanese biomedical biotechnology sector (for example pharmacogenomics and novel chemotherapeutics)
• Key insights on the impact of globalisation and emerging markets on Japan’s pharmaceutical and biotech industries
• How Japanese pharmaceutical companies are engaging with foreign direct investment (FDI)
• Analyse recent opportunities from FDI players
• Gaining venture capital support to invest in the JPM
• Maximising product longevity
• How generics manufacturers can penetrate this market
• Pipeline developments with blockbuster potential
• Currently marketed drugs with blockbuster potential
• Discussion of unmet therapeutic needs
• Ensuring safety and good manufacturing process when engaging in outsourcing to Japan
• Labelling and translating your product’s ingredients

Key speakers
• Findlay Walker, Vice President, EU Administration, Daiichi Sankyo
• Patrick Keohane, Vice President and Head of Japan and Asia Pacific R&D, AstraZeneca K.K. Japan
• Alan Wehnert, Vice President, Corporate Project Management, R&D, H. Lundbeck
• Shoichi Okuyama, Vice President, Japan Patent Attorneys Association
• Anastasia Liapi, Director, Business Development, Astellas Pharma Europe
• Michael Murray, Director of Business Development, Sosei
• Julian F. Burke, Chief Scientific Officer, Genetix
• Naoki Watanabe, Partner, Clifford Chance Japan
• Janet Knowles, Partner, Eversheds LLP
• Yuji Sato, Founding Professor, Centre for Clinical Research, Keio University
• Chizuko Koseki, Director and Co-Founder, TransB
• Martin Walter, Director, Simon-Kucher & Partners
• P. Reed Maurer, Founder and President, International Alliances
• Mondher Toumi, Executive Vice President, Creativ-Ceutical
• Fumihiko Ugajin, Japanese PPS Practice Leader, IMS Health
• Louis Turner, Chief Executive, Asia-Pacific Technology Network
• Paul Francis, Professor of Neurochemistry, King’s College London
• Maki Umemura, Faculty of Japanese Studies, Cardiff Business School

Who will be there:
VPs, CEO, CSO, Heads and Managers in:
• Mergers and acquisitions
• Venture capital
• Business/strategic development
• Pre-clinical/clinical R&D
• Clinical trials
• CNS/neuroscience/nervous system research
• Drug discovery/drug R&D/drug design
• International regulatory affairs
• Global marketing and medicine
• Diabetes/endocrinology
• Cardiovascular medicine
• Oncology
• Biotechnology/biosimilars
• Product lifecycle management
• Generics
• Government affairs and public policy
• Global pricing and reimbursement
• Pharmacoeconomics
• Pharmaceutical & patent law
• Outsourcing/contract manufacturing
• Personalised medicine/pharmacogenomics


BSG House
226-236 City Road
United Kingdom

Additional Information

Standard Prices: Conference only Fee: £999 VAT: £149.85 Total: £1148.85 Promotional Literature Distribution (Distribution of your company’s promotional literature to all conference attendees) Fee: £799 VAT: £119.85 Total: £918.85